The Molecular Epidemiology of de Novo and Treatment Related 11q23 Leukemia in the Young
OBJECTIVES:
- Characterize the clinical, morphologic, immunologic, cytogenetic, and molecular
heterogeneity of acute lymphoblastic leukemia or acute myeloid leukemia (AML) in
infants and monoblastic variants of AML in young patients.
- Characterize the clinical, morphologic, immunologic, cytogenetic, and molecular
heterogeneity of secondary AML in young patients.
- Compare secondary AML vs de novo AML at the level of Southern blot, breakpoint
sequence, and DNA topoisomerase II cleavage sites.
OUTLINE: This is a multicenter study.
Bone marrow or blood are collected and analyzed by Southern blot for chromosome 11q23
breakpoints and translocations. Samples from patients with secondary acute myeloid leukemia
are also examined for MLL gene rearrangements.
PROJECTED ACCRUAL: A total of 250 patients will be accrued for this study.
Observational
N/A
Clinical, morphologic, immunologic, cytogenetic, and molecular characteristics of acute lymphoblastic leukemia and de novo and secondary acute myeloid leukemia (AML)
No
Beverly J. Lange, MD
Study Chair
Children's Hospital of Philadelphia
United States: Federal Government
CDR0000538662
NCT00899652
Name | Location |
---|